Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (262)

Advertisement

Research Article Free access | 10.1172/JCI113373

Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen.

D T Woodley, R E Burgeson, G Lunstrum, L Bruckner-Tuderman, M J Reese, and R A Briggaman

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Woodley, D. in: JCI | PubMed | Google Scholar

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Burgeson, R. in: JCI | PubMed | Google Scholar

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Lunstrum, G. in: JCI | PubMed | Google Scholar

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Bruckner-Tuderman, L. in: JCI | PubMed | Google Scholar

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Reese, M. in: JCI | PubMed | Google Scholar

Department of Dermatology, University of North Carolina Medical School, Chapel Hill 27514.

Find articles by Briggaman, R. in: JCI | PubMed | Google Scholar

Published March 1, 1988 - More info

Published in Volume 81, Issue 3 on March 1, 1988
J Clin Invest. 1988;81(3):683–687. https://doi.org/10.1172/JCI113373.
© 1988 The American Society for Clinical Investigation
Published March 1, 1988 - Version history
View PDF
Abstract

Epidermolysis bullosa acquisita (EBA) is a severe, chronic blistering disease of the skin. EBA patients have circulating and tissue-bound autoantibodies to a large (Mr = 290,000) macromolecule that is localized within the basement membrane zone between the epidermis and dermis of skin, the site of blister formation. The "EBA antigen" is known to be distinct from laminin, heparan sulfate proteoglycan, fibronectin, the bullous pemphigoid antigen, elastin, and collagen types I, II, III, IV, and V. Sera from patients with EBA, two monoclonal antibodies to the EBA antigen, and a monoclonal antibody to the carboxyl terminus of type VII procollagen identically label human amnion and skin by immunofluorescent and immunoelectron microscopy. Western immunoblots of the EBA antigen extracted from skin and of type VII procollagen labeled with the above sera and antibodies are identical. None of the sera or antibodies labels Western blots of pepsinized type VII collagen which is missing the globular amino and carboxyl terminal domains. These data show that the EBA antigen is the carboxyl terminus of type VII procollagen.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 683
page 683
icon of scanned page 684
page 684
icon of scanned page 685
page 685
icon of scanned page 686
page 686
icon of scanned page 687
page 687
Version history
  • Version 1 (March 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (262)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts